Literature DB >> 3922392

Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.

B MacMahon, M Bakshi, P Branagan, J G Kelly, M J Walsh.   

Abstract

The pharmacokinetics and haemodynamic effects of tocainide, an orally active structural analogue of lignocaine, were studied in patients with acute myocardial infarction complicated by left ventricular failure. Fourteen patients (mean age 65 years) with acute myocardial infarction complicated by mild left ventricular failure were studied, following a single dose of tocainide (250 mg) by intravenous infusion, over 30 min. Heart rate, systemic arterial pressure, pulmonary artery pressure and cardiac output were monitored. Plasma tocainide levels were estimated by gas chromatography. The mean plasma level of tocainide achieved was 2.95 micrograms/ml (15.37 mmol/l). The mean plasma half-life was 15.6 h. The mean cardiac index was reduced 5 min after completion of the infusion, from 2.24 1 min-1 m-2 (+/- 0.40) to 2.07 1 min-1 m-2 (+/- 0.29) (P less than 0.01). At 90 min the cardiac index had returned to pre-treatment levels. Small changes were seen in the heart rate, arterial blood pressure and the pulmonary artery pressure but these changes were not statistically significant. The pharmacokinetics of tocainide were not significantly altered in patients with acute myocardial infarction complicated by mild left ventricular failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922392      PMCID: PMC1463818          DOI: 10.1111/j.1365-2125.1985.tb02666.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

Review 2.  The clinical pharmacology of lidocaine as an antiarrhythymic drug.

Authors:  K A Collinsworth; S M Kalman; D C Harrison
Journal:  Circulation       Date:  1974-12       Impact factor: 29.690

3.  Thermodilution cardiac output determination with a single flow-directed catheter.

Authors:  J S Forrester; W Ganz; G Diamond; T McHugh; D W Chonette; H J Swan
Journal:  Am Heart J       Date:  1972-03       Impact factor: 4.749

4.  Long-term oral antiarrhythmic therapy with mexiletine.

Authors:  N P Campbell; J F Pantridge; A A Adgey
Journal:  Br Heart J       Date:  1978-07

5.  Congestive heart failure caused by oral disopyramide.

Authors:  P J Podrid; A Schoeneberger; B Lown
Journal:  N Engl J Med       Date:  1980-03-13       Impact factor: 91.245

6.  Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction.

Authors:  C Graffner; T B Conradson; S Hofvendahl; L Rydén
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

7.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

8.  Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man.

Authors:  D G McDevitt; A S Nies; G R Wilkinson; R F Smith; R L Woosley; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

9.  Relation between infarct size and ventricular arrhythmia.

Authors:  R Roberts; A Husain; H D Ambos; G C Oliver; J R Cox; B E Sobel
Journal:  Br Heart J       Date:  1975-11

10.  The hemodynamic effects of intravenous tocainide in patients with heart disease.

Authors:  R A Winkle; J L Anderson; F Peters; P J Meffin; R E Fowles; D C Harrison
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

View more
  4 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 3.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.